Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biotron ( (AU:BIT) ) has shared an announcement.
Biotron Limited has appointed experienced life sciences executive and industrial chemist Graeme Wald as a non-executive director, effective 30 March 2026. Wald brings a strong background in pharmaceutical equity research, private equity and venture capital, and has been instrumental in raising more than $750 million for healthcare companies globally.
He currently holds leadership roles at several therapeutics companies focused on antibody-based treatments for solid tumours, prostate cancer and paediatric neuroblastoma. Biotron’s chairman said Wald’s appointment adds substantial expertise at a critical stage of the company’s new project developments, signalling a strengthening of its governance and strategic capabilities as it advances its pipeline.
The most recent analyst rating on (AU:BIT) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Biotron stock, see the AU:BIT Stock Forecast page.
More about Biotron
Biotron Limited is an Australian biotechnology company based in Sydney that focuses on developing therapeutic technologies, including new project developments in life sciences. The company operates within the broader pharmaceuticals and healthcare sector and is listed on the ASX, positioning it among early-stage biotechs seeking to advance novel treatments.
Technical Sentiment Signal: Sell
Current Market Cap: A$6.75M
See more insights into BIT stock on TipRanks’ Stock Analysis page.